18 November 2025
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Group")
Transaction in Own Shares
Venture Life Group plc (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that, in accordance with the terms of its share buyback programme announced on 30 September 2025, the Company has purchased 24,240 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") in the market at a volume weighted average price of 59.65 pence per Ordinary Share through Cavendish Capital Markets Limited ("Cavendish").
The Ordinary Shares acquired will be held as treasury shares.
Aggregated Information
| Date of Purchase: |
17 November 2025 |
| Aggregate Number of Ordinary Shares Purchased: |
24,240 |
| Lowest Price Paid per Ordinary Share (pence): |
59.65 |
| Highest Price Paid per Ordinary Share (pence): |
59.65 |
| Volume-Weighted Average Price Paid per Ordinary Share (pence): |
59.65 |
Following the repurchase of the Ordinary Shares, Venture Life will have 128,052,312 Ordinary Shares in issue, including 24,240 Ordinary Shares held in treasury.
The total number of voting rights in the Company is therefore 128,028,072. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
| Individual Transactions |
|||
| Number of Ordinary Shares purchased |
Transaction price (pence per Ordinary Share) |
Time of transaction |
Venue |
| 24,240 |
59.65 |
13:37 |
AIMX |
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys/George Lawson (Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.